Diagnosis and Management of Invasive Aspergillosis

Diagnostic Considerations

The Infectious Diseases Society of America recommends against using beta-D-glucan as a primary diagnostic tool for invasive aspergillosis in immunocompromised patients due to poor specificity, though it may provide modest incremental value when combined with galactomannan testing 1, 2
Beta-D-glucan cannot distinguish between Aspergillus, Candida, Fusarium, and Pneumocystis jirovecii infections, making it fundamentally non-specific for aspergillosis 3, 4, 6
The test detects a cell wall component present in multiple fungal genera, so a positive result only indicates some invasive fungal infection, not specifically Aspergillus 3, 6
In pediatric populations, guidelines explicitly recommend against using beta-D-glucan for screening or diagnosing invasive aspergillosis in high-risk immunocompromised children (D-III recommendation) 1, 2

Perform chest CT scan whenever invasive pulmonary aspergillosis is clinically suspected, regardless of chest X-ray findings (strong recommendation) 3, 6
Order serum galactomannan testing twice weekly in high-risk neutropenic patients (allogeneic HSCT, hematologic malignancies, prolonged profound neutropenia) 1, 2, 5
Use optical density index ≥0.5 in two consecutive samples as the diagnostic threshold 5
Consider bronchoalveolar lavage with galactomannan testing (cutoff ≥1.0) for improved sensitivity, especially in patients on mold-active prophylaxis 1, 6

Never diagnose aspergillosis based solely on positive beta-D-glucan without supporting clinical, radiographic, or microbiological evidence 5, 8
Systematically exclude false-positive causes: recent antibiotic administration (especially beta-lactams), hemodialysis, albumin/IVIG products, and bacteremia 3, 5
A negative beta-D-glucan does not rule out invasive aspergillosis, particularly in patients on antifungal therapy 7